AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1992660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO (higher doses)
Number of subjects: 12
Study 7045603 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol, Gist‐Brocades)
Number of subjects: 46
Study 7045603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30575602 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home auditory training program for 5 weeks
Number of subjects: 43
Study 30575602 — intervention group
Group type: COMPARATOR
Intervention: Audiobooks (active control)
Number of subjects: 43
Study 30575602 — intervention group
Group type: COMPARATOR
Intervention: Passive control (no intervention)
Number of subjects: 43
Study 30177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the MWP region
Number of subjects: 839
Study 30177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with DM2
Number of subjects: 839
Study 30177481 — intervention group
Group type: COMPARATOR
Intervention: All variables including 'GP practice'
Number of subjects: 839
Study 30177481 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 839
Study 26769016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL 7% hypertonic saline
Number of subjects: 132
Study 26769016 — intervention group
Group type: COMPARATOR
Intervention: 0.12% saline (control)
Number of subjects: 132
Study 24686785 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation judgment task with visual stimuli
Number of subjects: 0
Study 24686785 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention modulation
Number of subjects: 0
Study 24686785 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial and temporal proximity of stimuli
Number of subjects: 0
Study 21603966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (one-step self-etch adhesive)
Number of subjects: 26
Study 21603966 — intervention group
Group type: COMPARATOR
Intervention: Optibond FL (three-step etch-and-rinse adhesive)
Number of subjects: 26
Study 20110538 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin
Number of subjects: 4731
Study 20110538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 17122083 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosi (8 mg/d)
Number of subjects: 50
Study 17122083 — intervention group
Group type: COMPARATOR
Intervention: Rosi (1 μM)
Number of subjects: 50
Study 17122083 — intervention group
Group type: COMPARATOR
Intervention: Rosi (20 mg/kg·d)
Number of subjects: 50
Study 17122083 — intervention group
Group type: COMPARATOR
Intervention: Rosi treatment (1 μM)
Number of subjects: 50
Study 16275520 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic midwall fractional shortening after CoA
Number of subjects: 30
Study 16275520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine MR midwall fractional shortening after CoA
Number of subjects: 30
Study 16275520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional MR tagging midwall circumferential shortening in CoA group
Number of subjects: 30
Study 16275520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional MR tagging midwall longitudinal shortening in CoA group
Number of subjects: 30
Study 16275520 — intervention group
Group type: COMPARATOR
Intervention: Cine MR midwall shortening recalculated for through-plane motion
Number of subjects: 30
Study 12856053 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weeks of aminosidine (paromomycin) ointment
Number of subjects: 216
Study 12856053 — intervention group
Group type: COMPARATOR
Intervention: Two weeks of aminosidine (paromomycin) ointment and two weeks of placebo
Number of subjects: 216
Study 10625320 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 928
Study 10625320 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg
Number of subjects: 928
Study 10625320 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg
Number of subjects: 928
Study 8909908 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training
Number of subjects: 29
Study 8909908 — intervention group
Group type: COMPARATOR
Intervention: High-intensity training
Number of subjects: 29
Study 8909908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 1745027 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange, prednisolone, cyclophosphamide, and azathioprine
Number of subjects: 48
Study 1745027 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy only (control group)
Number of subjects: 48
Study 1745027 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (serum creatinine < 500 mumol/liter)
Number of subjects: 48
Study 1745027 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (serum creatinine > 500 mumol/liter but not on dialysis)
Number of subjects: 48
Study 6964655 — intervention group
Group type: EXPERIMENTAL
Intervention: Rayner Binkhorst pupil‐supported intraocular lens (IOL) calculated for emmetropia using biometric data
Number of subjects: 200
Study 6964655 — intervention group
Group type: COMPARATOR
Intervention: Standard power +19 D IOL
Number of subjects: 200
Study 31640891 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (measured in quintiles or 5 cm increments)
Number of subjects: 17263
Study 29094048 — intervention group
Group type: COMPARATOR
Intervention: Single-dose Praziquantel (40 mg/kg)
Number of subjects: 431
Study 29094048 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose Praziquantel (40 mg/kg)
Number of subjects: 431
Study 26727115 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages (ASB)
Number of subjects: 31
Study 26727115 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 31
Study 26727115 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverages (SSB)
Number of subjects: 31
Study 24903351 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 14
Study 24903351 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study 23053658 — intervention group
Group type: EXPERIMENTAL
Intervention: HA‐CMC (sodium hyaluronate‐carboxymethyl cellulose) applied to the surface of the pectoralis major and serratus anterior muscle after total mastectomy (n=50)
Number of subjects: 99
Study 23053658 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=49) - total mastectomy without HA‐CMC
Number of subjects: 99
Study 19229988 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose budesonide (9 mg/day for 7 weeks followed by 6 mg/day for 3 weeks)
Number of subjects: 70
Study 19229988 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with 12 mg/day for the first month followed by the same regimen as Group 1
Number of subjects: 70
Study 17698116 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative circulating plasminogen activator inhibitor type I
Number of subjects: 429
Study 17698116 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of plasminogen activator inhibitor type I to preoperative multivariate model
Number of subjects: 429
Study 17698116 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of plasminogen activator inhibitor type I to postoperative model
Number of subjects: 429
Study 10928308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride 100-300 mg/day
Number of subjects: 306
Study 10928308 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2-6 mg/day
Number of subjects: 306
Study 10928308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 8677757 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective chemotherapy in ANLL responders
Number of subjects: 43
Study 8677757 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy in ANLL responders
Number of subjects: 43
Study 8677757 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL responders
Number of subjects: 43
Study 8677757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders in ANLL
Number of subjects: 43
Study 8677757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders in ALL
Number of subjects: 43
Study 1591097 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA flow cytometry (DNI and SPF)
Number of subjects: 241
Study 3895775 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture technique
Number of subjects: 60
Study 3895775 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastomosis level
Number of subjects: 60
Study 3895775 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture line leakage at anastomosis
Number of subjects: 60
Study 31388914 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-FIVES (skills training program for caregivers)
Number of subjects: 241
Study 31388914 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-FIVES
Number of subjects: 241
Study 31388914 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study 29602597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs (monotherapy for 6 weeks)
Number of subjects: 118
Study 25968451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 300 mg/d)
Number of subjects: 301
Study 25968451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 25332243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon (HDI) for 1 year
Number of subjects: 432
Study 25332243 — intervention group
Group type: COMPARATOR
Intervention: Biochemotherapy (dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b, and granulocyte colony-stimulating factor every 21 days for three cycles)
Number of subjects: 432
Study 25332243 — intervention group
Group type: COMPARATOR
Intervention: Biochemotherapy
Number of subjects: 432
Study 22335365 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening method using the Prodromal Questionnaire and CAARMS assessment
Number of subjects: 0
Study 22335365 — intervention group
Group type: COMPARATOR
Intervention: Referral method to the diagnostic center using CAARMS assessment
Number of subjects: 0
Study 22335365 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening method
Number of subjects: 0
Study 20598976 — intervention group
Group type: EXPERIMENTAL
Intervention: Preintervention period (2002-2003)
Number of subjects: 125161
Study 20598976 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention period (2006-2007)
Number of subjects: 125161
Study 20598976 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 125161
Study 20598976 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 40 to 60 years
Number of subjects: 125161
Study 17573295 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus the COPE intervention
Number of subjects: 329
Study 17573295 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus friendly visits
Number of subjects: 329
Study 17573295 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 329
Study 15968712 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutin capsules (Julphar, UAE)
Number of subjects: 24
Study 15968712 — intervention group
Group type: COMPARATOR
Intervention: Prozac capsules (Eli Lilly, UK)
Number of subjects: 24
Study 12110467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of oral amphetamine
Number of subjects: 0
Study 12110467 — intervention group
Group type: COMPARATOR
Intervention: Acute schizophrenic patients
Number of subjects: 0
Study 12110467 — intervention group
Group type: COMPARATOR
Intervention: Chronic schizophrenic patients
Number of subjects: 0
Study 12110467 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers with high schizotypy scores
Number of subjects: 0
Study 10723224 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin concentration in patients with infective endocarditis
Number of subjects: 12
Study 10723224 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 12
Study 10723224 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of erythropoietin levels
Number of subjects: 12
Study 8822427 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisolone daily for 2 weeks prior to IVF treatment
Number of subjects: 53
Study 8822427 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 2 weeks prior to IVF treatment
Number of subjects: 53
Study 2200559 — intervention group
Group type: EXPERIMENTAL
Intervention: HAE
Number of subjects: 61
Study 2200559 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI with 5-fluorouracil and degradable starch microspheres
Number of subjects: 61
Study 2200559 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 61
Study 31980514 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 31980514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31399773 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 29453
Study 31399773 — intervention group
Group type: COMPARATOR
Intervention: Standard digital mammography (DM)
Number of subjects: 29453
Study 28863524 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized stochastic Redfield equation (GSRE) theory
Number of subjects: 0
Study 28863524 — intervention group
Group type: COMPARATOR
Intervention: Existing theory based on the extended Solomon equations
Number of subjects: 0
Study 26041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients free from orthodema at discharge (score=0)
Number of subjects: 496
Study 26041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low-grade orthodema at discharge
Number of subjects: 496
Study 26041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high-grade orthodema at discharge
Number of subjects: 496
Study 26041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without orthodema at discharge
Number of subjects: 496
Study 22936114 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Almonga'
Number of subjects: 0
Study 22936114 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Curruquilla'
Number of subjects: 0
Study 22936114 — intervention group
Group type: COMPARATOR
Intervention: Bread
Number of subjects: 0
Study 21810499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 0
Study 21810499 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein patch
Number of subjects: 0
Study 21810499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 20189669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyfix
Number of subjects: 24
Study 20189669 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Compression Plate (ACP)
Number of subjects: 24
Study 17660491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus platinum analog (oxaliplatin or cisplatin)
Number of subjects: 503
Study 17660491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus platinum analog (oxaliplatin or cisplatin) in patients with PS = 0
Number of subjects: 503
Study 17660491 — intervention group
Group type: COMPARATOR
Intervention: Single-agent gemcitabine
Number of subjects: 503
Study 16311849 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastrectomy with jejunal pouch interposition (PGJP)
Number of subjects: 51
Study 16311849 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy with Roux‐en‐Y esophagojejunostomy (TGRY)
Number of subjects: 51
Study 12542874 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid spinal analgesia with morphine sulfate (Group A)
Number of subjects: 20
Study 12542874 — intervention group
Group type: COMPARATOR
Intervention: No subarachnoid spinal analgesia (Group B)
Number of subjects: 20
Study 9708543 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation of the motor cortex in patients with migraine with aura during isometric contraction.
Number of subjects: 85
Study 9708543 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation of the visual cortex in patients with migraine with aura.
Number of subjects: 85
Study 9708543 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation of the motor cortex in patients with migraine without aura.
Number of subjects: 85
Study 9708543 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation of the visual cortex in healthy controls.
Number of subjects: 85
Study 7608408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic analysis of closing sounds of implanted prosthetic heart valves
Number of subjects: 0
Study 2093696 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol
Number of subjects: 30
Study 2093696 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphinpyrazone
Number of subjects: 30
Study 373871 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin (12 g/d)
Number of subjects: 43
Study 373871 — intervention group
Group type: COMPARATOR
Intervention: clindamycin (2.4 g/d) plus gentamicin (5.1 mg/kg daily)
Number of subjects: 43
Study 31482294 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 100
Study 31482294 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 100
Study 30972991 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial submergence treatment for 20 days
Number of subjects: 80
Study 30972991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice cv. TB (tolerant cultivar)
Number of subjects: 80
Study 30972991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice cultivars categorized by tolerance
Number of subjects: 80
Study 28263919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Index for Intensive Care after Allogeneic Hematopoietic Stem Cell Transplantation (PICAT)
Number of subjects: 656
Study 28263919 — intervention group
Group type: EXPERIMENTAL
Intervention: PICAT scores of 0 to 2
Number of subjects: 656
Study 28263919 — intervention group
Group type: EXPERIMENTAL
Intervention: PICAT scores of >2 to 4
Number of subjects: 656
Study 28263919 — intervention group
Group type: EXPERIMENTAL
Intervention: PICAT scores of >4
Number of subjects: 656
Study 28263919 — intervention group
Group type: COMPARATOR
Intervention: APACHE II
Number of subjects: 656
Study 28263919 — intervention group
Group type: COMPARATOR
Intervention: SOFA
Number of subjects: 656
Study 25795410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 272
Study 25795410 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy (ICC)
Number of subjects: 272
Study 25795410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 272
Study 23557077 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 296
Study 23557077 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 296
Study 21721594 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam autoinjector (10 mg)
Number of subjects: 48
Study 21721594 — intervention group
Group type: COMPARATOR
Intervention: Diazepam rectal gel (10 mg)
Number of subjects: 48
Study 19453040 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 5-FU infusion (333 mg/m2/day for 7 days starting from the day of surgery) + oral HCFU (300 mg/day for 2 years starting 2 weeks after surgery) in Group B
Number of subjects: 133
Study 19453040 — intervention group
Group type: COMPARATOR
Intervention: Oral HCFU (300 mg/day for 2 years starting 2 weeks after surgery) in Group A
Number of subjects: 133
Study 16426086 — intervention group
Group type: EXPERIMENTAL
Intervention: Journals with impact factors above 4 points
Number of subjects: 132
Study 16426086 — intervention group
Group type: COMPARATOR
Intervention: Journals with impact factors below 4 points
Number of subjects: 132
Study 16426086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published in journals with high, medium, and low impact factors (Jadad scale)
Number of subjects: 132
Study 16426086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials published in high-impact factor journals (Cochrane Collaboration Handbook quality criterion)
Number of subjects: 132
Study 15063918 — intervention group
Group type: EXPERIMENTAL
Intervention: Court-ordered disulfiram treatment
Number of subjects: 36
Study 15063918 — intervention group
Group type: COMPARATOR
Intervention: Voluntary disulfiram treatment
Number of subjects: 36
Study 10902414 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body space bisection
Number of subjects: 12
Study 10902414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body space bisection
Number of subjects: 12
Study 9018023 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gum containing sugar and aromatic additives
Number of subjects: 20
Study 9018023 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum containing 200 mg theanine
Number of subjects: 20
Study 9018023 — intervention group
Group type: COMPARATOR
Intervention: Gum base (no sugar, no aromatic additives)
Number of subjects: 20
Study 7688204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% 13-cis-retinoic acid cream
Number of subjects: 10
Study 7688204 — intervention group
Group type: COMPARATOR
Intervention: Cream base only (Control)
Number of subjects: 10
Study 3302865 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactams
Number of subjects: 0
Study 3302865 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 0
Study 29628452 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care interventions
Number of subjects: 0
Study 27746523 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 0.05 mg/kg
Number of subjects: 60
Study 27746523 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 1.5 mcg/kg
Number of subjects: 60
Study 24654464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphereline (GnRH agonist)
Number of subjects: 42
Study 24654464 — intervention group
Group type: COMPARATOR
Intervention: Control (no GnRH agonist)
Number of subjects: 42
Study 21497479 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 servings/day of low glycemic index (LGI) foods
Number of subjects: 2
Study 21497479 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 servings/day of low glycemic index (LGI) foods
Number of subjects: 2